Linked e-resources
Details
Table of Contents
Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC)
Promising biomarkers for early diagnosis and prognosis prediction in HNS
Biomarkers to predict radiotherapy toxicity
Biomarkers for hypoxia, HPVness and proliferation from imaging perspective
Mechanism of cetuximab resistance and how to overcome it
The role of liquid biopsy for monitoring disease evolution
NK cells in immunotherapy: how important are they?
Biomarkers for immune modulatory treatment in HNSCC
Primary disease (1)
Novel approaches in surgical management of HNSCC
The surgical approach to elderly patients with HNSCC
The nonsurgical approach to locoregionally advanced HNSCC
High-dose three-weekly or low-dose weekly cisplatin during radiation, what to prefer?
Primary disease (2)
Where and when to use induction chemotherapy?
Prognostic role of p16/HPV in non-oropharyngeal head and neck cancer
Is there a role for neoadjuvant targeted and immunotherapies?
Is there a role for adjuvant targeted and immunotherapies?
Optimal supportive measures during primary treatment
Precision Medicine in head and neck cancer: myth or reality
Recurrent and / or metastatic disease
Salvage surgery: candidates, safe reconstruction, and results?
Re-irradiation for local relapses or second primaries: when and how?
New promising targeted agents in first and second-line settings
Update of immune therapies in recurrent/metastatic HNSCC
Special Issue
Patients with rare head neck cancers: do they need a different approach? .-Nasopharynx cancer
New epidemiological aspects
New developments in the management of nasopharyngeal carcinoma
New drugs for recurrent/metastatic nasopharynx cancer.
Promising biomarkers for early diagnosis and prognosis prediction in HNS
Biomarkers to predict radiotherapy toxicity
Biomarkers for hypoxia, HPVness and proliferation from imaging perspective
Mechanism of cetuximab resistance and how to overcome it
The role of liquid biopsy for monitoring disease evolution
NK cells in immunotherapy: how important are they?
Biomarkers for immune modulatory treatment in HNSCC
Primary disease (1)
Novel approaches in surgical management of HNSCC
The surgical approach to elderly patients with HNSCC
The nonsurgical approach to locoregionally advanced HNSCC
High-dose three-weekly or low-dose weekly cisplatin during radiation, what to prefer?
Primary disease (2)
Where and when to use induction chemotherapy?
Prognostic role of p16/HPV in non-oropharyngeal head and neck cancer
Is there a role for neoadjuvant targeted and immunotherapies?
Is there a role for adjuvant targeted and immunotherapies?
Optimal supportive measures during primary treatment
Precision Medicine in head and neck cancer: myth or reality
Recurrent and / or metastatic disease
Salvage surgery: candidates, safe reconstruction, and results?
Re-irradiation for local relapses or second primaries: when and how?
New promising targeted agents in first and second-line settings
Update of immune therapies in recurrent/metastatic HNSCC
Special Issue
Patients with rare head neck cancers: do they need a different approach? .-Nasopharynx cancer
New epidemiological aspects
New developments in the management of nasopharyngeal carcinoma
New drugs for recurrent/metastatic nasopharynx cancer.